Solid Dispersion Extrudate for Pan-RAF Kinase Inhibitor Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pan-Raf kinase inhibitor Compound 1 faces challenges due to its low aqueous solubility and moderate log p, which limit its oral bioavailability and stability, necessitating improvements for effective cancer treatment.
Innovation Solution
A pharmaceutical composition comprising a solid dispersion extrudate of Compound 1 with a vinylpyrrolidinone-vinyl acetate copolymer, combined with pharmaceutically acceptable excipients, is developed to enhance bioavailability and stability, using an intermittent dosing regimen for improved cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound 1 is used as a pan-Raf kinase inhibitor for cancer treatment, then it shows potent inhibitory activity against wild-type and mutant Raf kinases, but its low aqueous solubility and moderate log p limit its oral bioavailability
Solution Approach 1:
The patent applies parameter changes by modifying the physical state of Compound 1 from crystalline to amorphous form, and by changing its molecular environment through incorporation into solid dispersion matrices and lipid-based carriers. These parameter changes in molecular arrangement and microenvironment significantly improve aqueous solubility and oral bioavailability while maintaining the compound's potent Raf kinase inhibitory activity
Solution Approach 2:
The patent employs composite materials by formulating Compound 1 with polymers, lipids, and other excipients to create solid dispersions, self-emulsifying drug delivery systems (SEDDS), and other composite formulations. These composite structures provide enhanced solubility, stability, and bioavailability through synergistic interactions between the drug and formulation components
2Reliability
If the dose of Compound 1 is increased to achieve higher drug exposure and better treatment efficacy, then cancer treatment effectiveness improves, but the side-effect profile becomes more concerning
Solution Approach 1:
The patent implements periodic action through intermittent dosing regimens (e.g., dosing on days 1, 8, and 15 of a 28-day cycle) rather than continuous daily dosing. This periodic administration maintains therapeutic drug exposure levels while allowing drug-free intervals that reduce cumulative toxicity and side effects, thereby improving the therapeutic index
Solution Approach 2:
The patent uses formulation components such as lipids, polymers, and surfactants as intermediaries that enhance drug solubility and bioavailability. These intermediary substances enable lower dosing requirements to achieve the same therapeutic effect, thereby reducing side effects while maintaining treatment efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves rapid dissolution and increased oral bioavailability, allowing for higher drug exposure and effective treatment of NRAS and BRAF-positive mutated cancers with a reduced side-effect profile.
Implementation Method 1
A pharmaceutical composition comprising a solid dispersion extrudate of Compound 1 with a vinylpyrrolidinone-vinyl acetate copolymer
Data Source
AI summary
The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.